FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesCarol Jarvis – European Knowledge Forum Patient Testimonial 2022
Topic: Conference
Video
Members
Understanding Blockchain and AI in the Clinical Supply Chain
Topics: Conference, Supply Chain
Video
Members
4G Clinical webinar - Mitigating Clinical Supply Chain Risk as the Pandemic Continues
Topics: COVID-19, Project Management, Supply Chain
Webinar
Free
